Drug intelligence / Profile preview

iQ-008

Development stage: Preclinical
Lead developer: iQure Pharma
Modality: Small Molecules
Administration: Oral

Overview

**iQ-008** is an orally available small-molecule multitargeting compound rationally designed to address neuropathic pain and neurodegenerative diseases. It modulates **calcium channels**, **sodium ion channels**, and **TRPV1**, exhibiting significant efficacy across multiple preclinical pain models following oral dosing and demonstrating promising results in zebrafish models for neurodegeneration.[1][3][4][10][16]

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on iQ-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iQ-008.

Explore the full profile